Pharma Leaders Weigh in On AI's Measurable Results In 2026
· Source: pharmtech.com
In short
ZS's 2027 CDIO study finds that pharma supply chain and manufacturing posted the biggest jump in measurable AI outcomes, rising from 29% in 2025 to 53% this year, while only 38% of organizations report measurable results across multiple functions. In an interview with Pharmaceutical Technology, ZS managing partner Mahmood Majeed explains how better data infrastructure, validated use cases and risk-tiered human oversight are moving AI from pilots into day-to-day GMP work. He also details the gaps in enterprise AI governance, validation approaches for GxP processes, sponsor-CDMO data responsibilities and the reskilling of manufacturing and quality staff.
Read Original Article — Read the full article on the publisher’s site.
In the issue of week 43, 2026: Amazon plans faster at scale as one customer cuts 52-week planning time 40%
Tags: pharma, manufacturing, forecasting, governance, GMP, validation